AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01633125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group music therapy
Description: The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
Study NCT01633125 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Group music therapy
Description: The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
Study NCT03842839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Inhalation Powder [Spiriva] 0.018mg
Description: Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
Study NCT03842839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol sulphate aerosol (Ventolin) 0.01mg
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
Study NCT03842839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate aerosol (Ventolin) 0.01mg
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
Study NCT03265106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BinD19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
Study NCT01448694 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: No treatment, only collecting observational data.
Study NCT04318158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: single shot US guided TAP block using 20 ml bupivacaine 0.25%.
Study NCT04318158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
Study NCT04318158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
Study NCT00160420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5mg Tablet, oral Daily for 12 months
Study NCT00765310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: R-alpha lipoic acid
Description: 600 mg in morning on empty stomach (two 300 mg capsules)
Study NCT00765310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two capsules once daily in morning on empty stomach
Study NCT00824980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP10.C8
Description: IP10.C8 Gel 1%
Study NCT00824980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IP10.C8
Description: IP10.C8 Gel 1%
Study NCT02978443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
Study NCT02978443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
Study NCT01472874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once a day Trientine
Description: Trientine at a dosage of \~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
Study NCT02536638 — intervention group
Intervention type: OTHER
Intervention: Exposure to pyelonephritis
Description: Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
Study NCT01092481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
Study NCT01092481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
Study NCT02936050 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diagnostic ultrasound
Description: All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
Study NCT03551314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intermittent Positive Pressure
Description: - NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle).
Study NCT03551314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: - CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle).
Study NCT00853502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone cypionate
Description: dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
Study NCT03877965 — intervention group
Intervention type: DRUG
Intervention: Digoxin
Description: Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
Study NCT03562065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion
Study NCT00117156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT00117156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT03371641 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASQ parental questionnaire
Description: ASQ parental questionnaire
Study NCT03371641 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Development scales
Description: WPPSI - IV and NEPSY development scales
Study NCT03371641 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Scale of Conners
Description: Scale of Conners
Study NCT03371641 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCQ Questionnaire
Description: SCQ questionnaire
Study NCT03371641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample (mother)
Description: Blood sample (mother) before delivery
Study NCT03371641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord blood sample
Description: Cord blood sample after delivery
Study NCT03371641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placenta sample
Description: Placenta sample
Study NCT01987817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR101 powder provided in capsules
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Study NCT01987817 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron 25 mg
Description: Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg
Description: Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg
Description: Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 5 mg
Description: Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 10 mg
Description: Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 25 mg matching placebo
Description: Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 50 mg matching placebo
Description: Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 5 mg matching placebo
Description: Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin 10 mg matching placebo
Description: Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study NCT01908829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 10 mg matching placebo
Description: Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study NCT04247997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: disconnect pulmonary vague nerve branches
Description: When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
Study NCT03054038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given by mouth
Study NCT03054038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Given IV
Study NCT03054038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03571737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen tablet
Study NCT03571737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen tablet
Study NCT03571737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Patch 4%
Description: Lidocaine patch
Study NCT03299764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pursed lip breathing ventilation
Description: A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
Study NCT03299764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-invasive ventilation
Description: Standard non-invasive ventilation
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
Study NCT04665856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiragolumab Matching Placebo
Description: Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Study NCT00066430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infrared photocoagulation therapy
Study NCT00066430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Coagulator
Description: IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
Study NCT02523222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 40% Dextrose gel
Description: 40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
Study NCT04073810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET imaging
Description: Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
Study NCT04073810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: CTCA at baseline and 2 years
Study NCT04073810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year
Study NCT01435655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: tafamidis meglumine 20 mg QD
Study NCT02030730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Seminar Series
Description: The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
Study NCT05446610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented product of Pleurotus eryngii mushroom
Description: I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
Study NCT01915576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1125976
Description: Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
Study NCT01915576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1125976
Description: Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
Study NCT01915576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1125976
Description: Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
Study NCT01870388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT02390934 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium 223
Study NCT00893399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (Mylotarg)
Description: Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO
Study NCT00893399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy
Description: Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
Study NCT00893399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy
Description: Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
Study NCT06259383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 3-day 1 daily dose of 400 μg/kg oral ivermectin
Study NCT01003925 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard of care for osteoarthritis treatment
Description: Standard of care educational materials to inform patients about choices for knee pain.
Study NCT01003925 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conjoint Analysis for Osteoarthritis
Description: Conjoint Analysis computer software to inform patients about choices for knee pain.
Study NCT01170416 — intervention group
Intervention type: OTHER
Intervention: 12-lead body surface mapping
Description: An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
Study NCT00968435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bevacizumab, cisplatin, cetuximab, radiation therapy
Description: Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
Study NCT01919359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multizyme Cellular Vitality Cyruta Plus SHEP
Study NCT01919359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multizyme Cellular Vitality Cyruta Plus SHEP
Study NCT01970852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard tablet computer
Description: No special enhancements or links to personal health information.
Study NCT01970852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced tablet computer
Description: Tablet computer with personalized access to data from the patient's electronic health record.
Study NCT04524598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limbix Spark
Description: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.
Study NCT04524598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.